What is Hypereosinophilic Syndrome Market?
Hypereosinophilic Syndrome (HES) is a group of rare blood disorders that occurs when an individual's blood has very high numbers of eosinophils. Eosinophils are a type of white blood cells formed in the bone marrow. In this syndrome, a continuous increase in the eosinophil count in the blood for at least six months, without any specific underlying cause. The standard treatment involves glucocorticosteroid medications such as prednisone, and chemotherapeutic agents such as hydroxyurea, chlorambucil and vincristine. It also involves Interferon-alpha drug that must be administered by frequent injections.
The market study is being classified and major geographies with country level break-up.
GlaxoSmithKline plc (United Kingdom), Bristol-Myers Squibb Company (United States), Kyowa Hakko Kirin Co., Ltd. (Japan), Knopp Biosciences LLC (United States), Stemline Therapeutics, Inc. (United States), F. Hoffmann-La Roche AG (Switzerland), Novartis International AG (Switzerland), Teva Pharmaceutical Industries Ltd (Israel), Pfizer Inc (United States) and AstraZeneca plc (United Kingdom) are some of the key players profiled in the study.
The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Hypereosinophilic Syndrome market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Hypereosinophilic Syndrome market by Type, Application and Region.
On the basis of geography, the market of Hypereosinophilic Syndrome has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increased Prevalence of Hypereosinophilic Syndrome
- Increased Number of Diagnostic Centres
- Growing Research and Development Investments
- Increasing Awareness among People
- Rise in the Online Pharmacies
- Lack of Knowledge about Hypereosinophilic Syndrome
- Poor Healthcare infrastructure in Developing Countries
- Huge Investments by Major Players
- Growth in the Healthcare Industry
- High Treatment Cost of Hypereosinophilic Syndrome
In September 2020, GlaxoSmithKline plc has announced the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) for the treatment of adult and paediatric patients aged 12 years and older with Hypereosinophilic Syndrome (HES) for ≥ six months without an identifiable non-haematologic secondary cause. The approval makes Nucala the first and only targeted biologic treatment to be approved for patients with this eosinophil-driven disease in the US.
Key Target AudienceHypereosinophilic Syndrome Treatment Providers, Emerging Companies, Research Professionals and End-users
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase